+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Moclobemide safety: monitoring a newly developed product in the 1990s

Moclobemide safety: monitoring a newly developed product in the 1990s

Journal of Clinical Psychopharmacology 15(4 Suppl 2): 76s-83s

Moclobemide is a reversible and selective inhibitor of monoamine oxidase subtype A with a wide spectrum of antidepressant activity. To fully evaluate product safety, Roche Drug Safety has collected data on adverse events (AEs), regardless of causality, from all sources worldwide through the product development phase and after launch. This effort has included analyses of reports from clinical trials, regulatory authorities, the literature, observational studies, and the marketplace. Roche Drug Safety has also carefully examined all cases where moclobemide was taken in overdose, whether with or without other substances. This article presents the safety profile of the product after 3 years on world markets. In clinical trials, moclobemide appeared only slightly less well tolerated than placebo. In comparative trials, moclobemide was largely devoid of the anticholinergic effects associated with tricyclic antidepressants. To the end of June 1993, with an estimated 780,000 subjects exposed, AEs had been reported by less than 0.2% of users. The most frequently reported AEs were psychiatric, neurologic, and gastrointestinal disorders. Hepatobiliary AEs were rare, suggesting that moclobemide is largely devoid of hepatotoxic potential. Cardiovascular AEs reflected the prevalence of cardiovascular disease in the population treated. This safety profile is largely unchanged from those observed at 1 and 2 years postlaunch, when the estimated exposed populations were 168,000 and 328,000, respectively. It is of great significance that the fatal toxicity index of moclobemide is zero. A review of single-drug intoxications with moclobemide at doses of up to 20.55 g revealed no deaths due solely to moclobemide overdose. All patients recovered fully within 1 to 7 days without residual hepatic or cardiovascular toxicity. There is no evidence of an increased risk of suicidal behavior in users of moclobemide. Close compound monitoring through development and after launch has confirmed the safety of moclobemide in therapeutic doses and in overdose.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 009029912

Download citation: RISBibTeXText

PMID: 7593735

Related references

Natural product synthesis as a challenging test of newly developed methodology. Chemical Communications 48(98): 11924-11938, 2012

Reaction of stored-product insects to some newly developed whole wheat products. 1970

Histopathological safety evaluation of newly-developed MgO sealer. European Journal of Medical Research 16(12): 526-530, 2011

Efficacy, safety and indication of newly developed insulin analogs. Nihon Rinsho. Japanese Journal of Clinical Medicine 59(11): 2165-2172, 2001

Evaluation of visceral impairments by exercise testing: practice and problems in recently-developed exercise testing in disabled patients and an introduction of a newly-developed instrument for monitoring cardiopulmonary and postural parameters. Rinsho Byori. Japanese Journal of Clinical Pathology 47(12): 1149-1158, 1999

An overview of a few well-known national children's gun safety programs and ENA's newly developed program. Journal of Emergency Nursing: Jen 27(5): 485-488, 2001

Evaluation of the Performance and Safety of a Newly Developed Intravenous Fluid Warmer. Artificial Organs 39(7): 591-596, 2015

How to "validate" newly developed cardiac output monitoring devices. Journal of Clinical Monitoring and Computing 30(2): 147-148, 2016

Safety evaluation of a newly-developed dietary fiber: resistant glucan mixture. Journal of Toxicological Sciences 41(1): 33-44, 2016

Efficiency and safety of newly developed therapeutic plasma separator composed of polysulfone. Japanese Journal of Artificial Organs 19(2): 974-977, 1990

Monitoring low level hepatitis B virus by a newly developed sensitive test. Hepatology Research 26(4): 281-286, 2003

Non-invasive monitoring of hemodynamic changes during hemodialysis by the use of a newly developed admittance cardiograph. Therapeutic Apheresis and Dialysis 9(2): 154-160, 2005

Comparison of the newly developed MYCOACID system with mycobacteria growth indicator tube (MGIT) and newly developed 2% Ogawa medium (S) for recovery of mycobacteria in clinical specimens. Kekkaku 76(12): 729-739, 2001

Evaluation of the clinical safety and efficacy of a newly developed 308-nm excimer lamp for vitiligo vulgaris. Journal of Dermatology 39(6): 559-561, 2012